PL2838892T3 - Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego - Google Patents

Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego

Info

Publication number
PL2838892T3
PL2838892T3 PL13719344T PL13719344T PL2838892T3 PL 2838892 T3 PL2838892 T3 PL 2838892T3 PL 13719344 T PL13719344 T PL 13719344T PL 13719344 T PL13719344 T PL 13719344T PL 2838892 T3 PL2838892 T3 PL 2838892T3
Authority
PL
Poland
Prior art keywords
low
anamolerin
chloride
organic solvent
molar ratio
Prior art date
Application number
PL13719344T
Other languages
English (en)
Polish (pl)
Inventor
Shin-Itsu Kuwabe
Takehiko YANAGIMACHI
Hideyuki YOSHIYAMA
Eleanor DE GROOT
Silvina Garcia Rubio
Peter Manini
Seemon Pines
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2838892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PL2838892T3 publication Critical patent/PL2838892T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13719344T 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego PL2838892T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
EP13719344.7A EP2838892B1 (en) 2012-04-20 2013-04-18 Isolated solid form of anamorelin monohydrochloride with low molar ratio of chloride:anamolerin and low content of residual organic solvent
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Publications (1)

Publication Number Publication Date
PL2838892T3 true PL2838892T3 (pl) 2018-05-30

Family

ID=48225135

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13719344T PL2838892T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny z niskim stosunkiem molowym chlorek:anamorelina i niską zawartością resztkowego rozpuszczalnika organicznego
PL17192651T PL3290410T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny o niskim stosunku molowym chlorek : anamorelina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17192651T PL3290410T3 (pl) 2012-04-20 2013-04-18 Wyodrębniona stała postać monochlorowodorku anamoreliny o niskim stosunku molowym chlorek : anamorelina

Country Status (47)

Country Link
US (8) US20140018391A1 (enrdf_load_stackoverflow)
EP (3) EP3517532B1 (enrdf_load_stackoverflow)
JP (3) JP6109925B2 (enrdf_load_stackoverflow)
KR (2) KR101972998B1 (enrdf_load_stackoverflow)
CN (3) CN103857669B (enrdf_load_stackoverflow)
AP (1) AP2014008013A0 (enrdf_load_stackoverflow)
AR (1) AR090725A1 (enrdf_load_stackoverflow)
AU (1) AU2013249197B2 (enrdf_load_stackoverflow)
BR (1) BR112014025972A8 (enrdf_load_stackoverflow)
CA (2) CA3031652C (enrdf_load_stackoverflow)
CL (1) CL2014002817A1 (enrdf_load_stackoverflow)
CO (1) CO7131356A2 (enrdf_load_stackoverflow)
CR (1) CR20140530A (enrdf_load_stackoverflow)
CY (1) CY1120276T1 (enrdf_load_stackoverflow)
DK (2) DK3517532T3 (enrdf_load_stackoverflow)
DO (1) DOP2014000235A (enrdf_load_stackoverflow)
EA (1) EA031581B1 (enrdf_load_stackoverflow)
EC (1) ECSP14027739A (enrdf_load_stackoverflow)
ES (2) ES2820354T3 (enrdf_load_stackoverflow)
GE (1) GEP20186902B (enrdf_load_stackoverflow)
HK (1) HK1248694A1 (enrdf_load_stackoverflow)
HR (1) HRP20180316T1 (enrdf_load_stackoverflow)
HU (2) HUE050865T2 (enrdf_load_stackoverflow)
IL (1) IL235064B (enrdf_load_stackoverflow)
JO (1) JO3353B1 (enrdf_load_stackoverflow)
LT (1) LT2838892T (enrdf_load_stackoverflow)
MA (1) MA37524B1 (enrdf_load_stackoverflow)
MD (1) MD4615C1 (enrdf_load_stackoverflow)
ME (1) ME02966B (enrdf_load_stackoverflow)
MX (1) MX354793B (enrdf_load_stackoverflow)
MY (1) MY170068A (enrdf_load_stackoverflow)
NI (1) NI201400124A (enrdf_load_stackoverflow)
NO (1) NO2877697T3 (enrdf_load_stackoverflow)
NZ (1) NZ700833A (enrdf_load_stackoverflow)
PE (1) PE20150084A1 (enrdf_load_stackoverflow)
PH (1) PH12014502351B1 (enrdf_load_stackoverflow)
PL (2) PL2838892T3 (enrdf_load_stackoverflow)
PT (2) PT3517532T (enrdf_load_stackoverflow)
RS (1) RS56869B1 (enrdf_load_stackoverflow)
SG (2) SG10201608488RA (enrdf_load_stackoverflow)
SI (2) SI3290410T1 (enrdf_load_stackoverflow)
TN (1) TN2014000421A1 (enrdf_load_stackoverflow)
TW (2) TWI677494B (enrdf_load_stackoverflow)
UA (1) UA116207C2 (enrdf_load_stackoverflow)
UY (1) UY34753A (enrdf_load_stackoverflow)
WO (1) WO2013158874A1 (enrdf_load_stackoverflow)
ZA (1) ZA201408508B (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
MA40607B1 (fr) 2014-09-04 2019-11-29 Helsinn Healthcare Sa Traitements médicaux à base d'anamoréline
KR20180030825A (ko) 2015-07-24 2018-03-26 뉴링크 제네틱스 코퍼레이션 1-메틸-d-트립토판의 염 및 프로드러그
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
CN114630655A (zh) * 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
WO2006016995A1 (en) 2004-06-29 2006-02-16 Sapphire Therapeutics, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
NZ700833A (en) 2016-01-29
CA2869893C (en) 2019-03-05
US20150072934A1 (en) 2015-03-12
NO2877697T3 (enrdf_load_stackoverflow) 2018-10-13
AP2014008013A0 (en) 2014-10-31
JO3353B1 (ar) 2019-03-13
US9981002B2 (en) 2018-05-29
HRP20180316T1 (hr) 2018-04-06
HUE035697T2 (en) 2018-05-28
AU2013249197B2 (en) 2017-04-06
NI201400124A (es) 2015-09-21
SI3290410T1 (sl) 2020-11-30
RS56869B1 (sr) 2018-04-30
US10905737B2 (en) 2021-02-02
MX354793B (es) 2018-03-21
EP3290410B1 (en) 2020-07-01
MD4615B1 (ro) 2019-01-31
KR20190044697A (ko) 2019-04-30
DOP2014000235A (es) 2015-01-31
CL2014002817A1 (es) 2015-08-14
MA37524B1 (fr) 2017-04-28
EA031581B1 (ru) 2019-01-31
BR112014025972A8 (pt) 2021-06-22
US20160237115A1 (en) 2016-08-18
DK2838892T3 (en) 2018-03-12
KR102141323B1 (ko) 2020-08-05
GEP20186902B (en) 2018-10-25
EP2838892B1 (en) 2017-12-06
CA3031652C (en) 2020-10-27
KR20150013115A (ko) 2015-02-04
US20140018391A1 (en) 2014-01-16
TWI677494B (zh) 2019-11-21
BR112014025972A2 (pt) 2017-06-27
JP6109925B2 (ja) 2017-04-05
CY1120276T1 (el) 2019-07-10
US10300105B2 (en) 2019-05-28
ES2820354T3 (es) 2021-04-20
EP2838892A1 (en) 2015-02-25
US20190000914A1 (en) 2019-01-03
JP6616853B2 (ja) 2019-12-04
UA116207C2 (uk) 2018-02-26
EP3517532B1 (en) 2021-10-13
US9403867B2 (en) 2016-08-02
US20160235804A1 (en) 2016-08-18
DK3517532T3 (da) 2022-01-03
US10576122B2 (en) 2020-03-03
JP2015514779A (ja) 2015-05-21
PT3517532T (pt) 2021-11-08
PH12014502351A1 (en) 2015-01-12
US9872883B2 (en) 2018-01-23
CN110041304A (zh) 2019-07-23
CA2869893A1 (en) 2013-10-24
MA37524A1 (fr) 2016-06-30
SG11201406478XA (en) 2014-11-27
KR101972998B1 (ko) 2019-04-29
HK1202863A1 (en) 2015-10-09
AR090725A1 (es) 2014-12-03
CO7131356A2 (es) 2014-12-01
JP2017101082A (ja) 2017-06-08
MY170068A (en) 2019-07-03
MX2014012178A (es) 2015-08-05
UY34753A (es) 2013-11-29
TW201348224A (zh) 2013-12-01
EA201401151A1 (ru) 2015-06-30
CN110041398A (zh) 2019-07-23
US20160229889A1 (en) 2016-08-11
US9956261B2 (en) 2018-05-01
PH12014502351B1 (en) 2015-01-12
CR20140530A (es) 2015-03-25
PE20150084A1 (es) 2015-01-23
EP3290410A1 (en) 2018-03-07
TWI589572B (zh) 2017-07-01
SI2838892T1 (en) 2018-05-31
ES2658862T3 (es) 2018-03-12
HUE050865T2 (hu) 2021-01-28
MD20140122A2 (ro) 2015-05-31
TN2014000421A1 (en) 2016-03-30
JP2018076375A (ja) 2018-05-17
PL3290410T3 (pl) 2021-01-11
MD4615C1 (ro) 2019-08-31
CN103857669B (zh) 2019-06-28
US20190231843A1 (en) 2019-08-01
WO2013158874A1 (en) 2013-10-24
HK1248694A1 (en) 2018-10-19
CA3031652A1 (en) 2013-10-24
JP6284665B2 (ja) 2018-02-28
IL235064A0 (en) 2014-12-31
TW201722928A (zh) 2017-07-01
AU2013249197A1 (en) 2014-10-30
CN103857669A (zh) 2014-06-11
ME02966B (me) 2018-07-20
IL235064B (en) 2019-09-26
EP3517532A1 (en) 2019-07-31
US20200276259A1 (en) 2020-09-03
PT2838892T (pt) 2018-02-28
ZA201408508B (en) 2020-01-29
LT2838892T (lt) 2018-03-12
SG10201608488RA (en) 2016-12-29
ECSP14027739A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
SI2825954T1 (sl) Primerjava območja vektorskih nizov
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
EP2867896A4 (en) RHYTHM OF CONTENT
SI2920149T1 (sl) Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin
IL234590A0 (en) Modified pyrazole-containing compounds and their use as pesticides
EP2810482A4 (en) IMPROVED MOBILITY WITH DISCONTINUOUS RECEPTION USING THE STATE OF MOBILITY
EP2956898A4 (en) TECHNIQUES FACILITATING THE PROMOTION OF ORGANIC CONTENT
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
ZA201503367B (en) Heteroaryl derivatives and uses thereof
AP3611A (en) Heterocyclic compounds and their uses
EP2928385A4 (en) ROTATING HANDLE ANCHORS AND METHODS OF USE
SG11201406529UA (en) Storage and stabilization of acetylene
RS56869B1 (sr) Izolovani čvrsti oblik anamorelin monohidrohlorida sa niskim molarnim odnosom hlorida:anamolerina i niskim sadržajem rezidualnog organskog rastvarača
GB2486025B (en) Content searching
GB2503216B (en) Continuity of content
PL2882708T3 (pl) Nowe związki i ich zastosowania
GB201222342D0 (en) Compounds and uses thereof
GB201215716D0 (en) Palletising of composted organic matter
GB201206973D0 (en) New compounds and uses
GB201207075D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses
GB201206998D0 (en) New compound and uses